This Week’s Best Performing ASX Stocks – 3rd October 2025

Australian stocks have pushed higher this week, with the main ASX 200 index gaining 2.01% over the last 7 days. The Technology and Healthcare sectors led the way in a week that saw the release of Purchasing Managers’ Index (PMI) data which provided mixed signals. In this article we look at three ASX stocks that have made significant gains in the last week. We have focused on mid-sized companies and larger here – companies with a market cap of at least 1 billion AUD.

Clarity Pharmaceuticals (CU6) +19.29%

Clarity Pharmaceuticals Ltd. (CU6.AX) has emerged as one of this week’s top ASX stocks, witnessing a significant surge of 19.29% in its stock price. The catalyst behind this impressive rally is the announcement of compelling pre-clinical data concerning its innovative pan-cancer theranostic, signaling optimism about the company’s future prospects.

Bolstering investor confidence, Clarity Pharmaceuticals successfully completed an A$203 million institutional placement in July 2025, priced at A$4.20 per share. This substantial capital infusion is earmarked for advancing Clarity’s clinical programs, with a particular focus on the development of SAR-bisFAP and other pipeline products. The successful fundraising underscores the market’s strong belief in the company’s strategic direction and growth potential.

Clarity’s pipeline expansion with SAR-bisFAP, an optimized FAP-targeted radiopharmaceutical, has further fueled positive sentiment. Pre-clinical studies have indicated that SAR-bisFAP offers increased tumor uptake and retention compared to existing FAP-targeted compounds. The company anticipates commencing a Phase I clinical trial for SAR-bisFAP in late 2025, focusing on cancers with significant unmet medical needs, reflecting the company’s commitment to innovation.

Adding to the positive momentum, Clarity Pharmaceuticals dosed the first patient in its pivotal Phase III CLARIFY trial in December 2023. This trial evaluates ⁶⁴Cu-SAR-bisPSMA for detecting regional nodal metastases in high-risk prostate cancer patients prior to radical prostatectomy, the trial aims to recruit 383 participants across multiple sites in the United States and Australia. Positive outcomes from this study could pave the way for regulatory approval, strengthening Clarity’s position in the prostate cancer diagnostic market.

Despite reporting a 37% increase in loss to $23.58 million for the half-year ended December 31, 2024, Clarity’s net tangible assets per security rose from 20.2 cents to 39.7 cents, indicating a stronger asset base. The company’s financial position, coupled with its innovative strategies and recent agreements, has led analysts to maintain a ‘Buy’ rating on the stock, reinforcing market optimism.

Bull Case

• Promising pre-clinical data for its pan-cancer theranostic, ⁶⁴/⁶⁷Cu-SAR-bisFAP, showing superior tumor targeting and retention.
• Successful A$203 million capital raise, indicating strong investor confidence and providing a solid financial runway for clinical programs.
• Strategic pipeline expansion with SAR-bisFAP, targeting a wide array of cancers with significant unmet needs.
• Advancement of the pivotal Phase III CLARIFY trial for prostate cancer diagnostics, moving closer to potential regulatory approval.
• Analysts maintain a ‘Buy’ rating on the stock, reinforcing a positive market outlook.

Bear Case

• The company remains unprofitable, reporting an increased loss of $23.58 million in its latest half-year results.
• Success is heavily dependent on the outcomes of ongoing and future clinical trials, which carry inherent risks and uncertainties.
• The promising SAR-bisFAP is still in the pre-clinical stage, with a Phase I trial not expected until 2026, indicating a long road to commercialization.
• As a clinical-stage biotechnology company, its stock price can be highly volatile and sensitive to clinical data releases and regulatory news.

Dateline Resources (DTR) +19.27%

Dateline Resources (ASX:DTR) has emerged as one of the top performing ASX stocks this week, buoyed by its inclusion in multiple key indices and signs of improving financial health. The stock has gained 19.27%, reflecting growing market confidence in the company’s strategic direction.

The recent surge in Dateline Resources’ stock price is underpinned by its admission to the S&P/ASX All Ordinaries Index, the S&P/ASX Emerging Companies Index, and the S&P Global BMI Index. Effective September 22, 2025, the inclusion in the S&P/ASX All Ordinaries Index, which represents the 500 largest companies listed on the Australian Securities Exchange (ASX) by market capitalization, is expected to enhance Dateline’s market visibility and liquidity. Index inclusion typically attracts attention from index-tracking funds and institutional investors, potentially broadening the company’s shareholder base and increasing trading volumes.

Further bolstering market sentiment is Dateline’s improving financial performance. The company’s latest annual earnings report indicated a narrowing of net losses compared to the previous year. This positive trend suggests progress toward financial stability and may attract investors seeking turnaround stories. Reinforcing this narrative, Dateline Resources successfully completed a $25 million institutional placement on September 2, 2025, priced at $0.215 per share. The capital raised is earmarked for accelerating development at the Colosseum Gold and Rare Earth Project, highlighting the company’s commitment to advancing its key assets.

Dateline Resources’ strategic acquisitions and project developments are also contributing to its positive market outlook. On September 15, 2025, the company acquired 100% of the Argos Strontium Project, recognized as America’s largest known strontium deposit. This acquisition aligns with U.S. efforts to secure domestic mineral supplies and diversifies Dateline’s portfolio. Additionally, the company has initiated an accelerated drilling program at the Colosseum Gold-REE Project, aiming to expedite exploration and development activities. These strategic moves demonstrate a proactive approach to growth and resource development.

Insider confidence, as reflected in recent transactions, further supports the positive market sentiment. On June 24, 2025, Managing Director Stephen Baghdadi invested approximately A$1.06 million by purchasing 53,000,208 shares at an average price of A$0.02 per share. Such substantial insider buying is often interpreted as a strong vote of confidence in the company’s future prospects.

Over the past year, Dateline’s stock has surged by 65%, with a more than threefold increase in the past quarter alone. This remarkable performance reflects growing optimism about the company’s strategic direction and operational progress. However, markets should consider whether the current stock price fully reflects future growth potential or if there remains additional value to be realized.

Bull Case

• Inclusion in the S&P/ASX All Ordinaries, Emerging Companies, and Global BMI indices, which is expected to enhance market visibility and liquidity.
• Improving financial performance with narrowing net losses reported in the latest annual earnings.
• Successful completion of a $25 million institutional placement to accelerate project development.
• Strategic acquisition of the Argos Strontium Project, the largest known strontium deposit in the U.S.
• Strong insider confidence demonstrated by a significant A$1.06 million share purchase by the Managing Director.

Bear Case

• The company is not yet profitable, as indicated by an N/A Price-to-Earnings (P/E) ratio.
• The stock has risen more than threefold in the last quarter, raising concerns that it may be overvalued or due for a correction.
• Future success is contingent on the company’s ability to execute its strategic plans, posing a significant execution risk.
• Valuation concerns exist as the market may have already priced in much of the future growth potential.

Eagers Automotive (APE) +15.28%

Eagers Automotive (APE.AX) has emerged as one of the ASX stocks making significant gains this week, fueled by its strategic acquisition of a majority stake in CanadaOne Auto. The market has reacted positively, driving a notable increase in the company’s stock value.

The week saw Eagers Automotive shares jump by 15.28%, reflecting growing market confidence following the announcement of its acquisition of a 65% stake in CanadaOne Auto for A$1.04 billion (US$687.54 million). The deal marks Eagers’ entry into the North American market, signaling a significant step in its international expansion strategy.

Analysts at Jefferies project that the acquisition could boost Eagers Automotive’s earnings by 15%. This expectation has further fueled market enthusiasm. However, Jefferies maintains an ‘underperform’ rating on the stock, with an unchanged price target of A$18. This seemingly contradictory stance highlights a potential concern regarding the valuation of Eagers post-acquisition, with the company expected to trade at 23 times its FY25 earnings, significantly higher than the North American sector average of 11 times the price-to-earnings ratio.

Beyond the CanadaOne deal, Eagers Automotive has demonstrated robust financial performance. The company reported an 18.9% increase in revenue, reaching $6,496,689. This positive financial momentum is further supported by a declared interim dividend of 24.0 cents, with a record date of September 8, 2025.

Eagers Automotive is also broadening its strategic investments. A recent partnership with Mitsubishi Corporation involves the acquisition of a 20% equity interest in Eagers’ pre-owned car business, easyauto123, for A$70 million. This move underscores Eagers’ commitment to growth and innovation within the automotive retail sector, both domestically and internationally.

The acquisition of CanadaOne Auto is anticipated to close in the first quarter of 2026, subject to regulatory approvals. The existing leadership team at CanadaOne, led by CEO Pat Priestner, will continue to manage the company post-acquisition. This continuity is expected to facilitate a smooth transition and leverage the combined expertise of both entities.

The contrasting perspectives from the market and Jefferies highlight the complexities surrounding Eagers Automotive’s valuation post-acquisition. While the market is responding positively to the growth potential, concerns remain about the elevated price-to-earnings ratio compared to industry peers.

Bull Case

• Strategic acquisition of a 65% stake in CanadaOne Auto, marking entry into the North American market for diversification and growth.
• The acquisition is projected by Jefferies analysts to boost earnings by 15%.
• Reported record revenue of $9.9 billion in 2023, a 15.3% increase year-over-year.
• Underlying operating profit before tax grew 6.9% to $433.3 million.
• A new partnership with Mitsubishi Corporation, which invested A$70 million for a 20% stake in the Easyauto123 used-car business.

Bear Case

• Jefferies maintains an ‘underperform’ rating on the stock despite the positive acquisition news.
• The post-acquisition valuation is expected to be 23 times FY25 earnings, significantly higher than the North American sector average of 11x, suggesting potential overvaluation.
• The international expansion introduces currency exposure risks.
• The Canadian automotive sector is cyclical, which could impact future performance.